Neoleukin Therapeutics Inc
Change company Symbol lookup
Select an option...
NLTX Neoleukin Therapeutics Inc
CTO CTO Realty Growth Inc
WHR Whirlpool Corp
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.

Closing Price
$0.59
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
40,499

10-day average volume:
60,091
40,499

Palantir Technologies Inc. (PLTR) Equity Notice: Robbins LLP is Investigating Palantir Technologies Inc. (PLTR) on Behalf of Shareholders

4:05 pm ET November 25, 2022 (BusinessWire) Print

The Class: Shareholder rights law firm Robbins LLP is investigating the officers and directors of Palantir Technologies Inc. (NYSE: PLTR) and its officers and directors to determine whether they breached fiduciary duties or violated securities laws. Palantir builds and deploys software platforms to assist the U.S. intelligence community in counterterrorism investigations and operations.

If you would like more information about our investigation of Palantir Technology Inc.'s misconduct, click here.

What is this Case About: Palantir Technologies Inc. (PLTR) Mislead Investors Regarding its Financial Prospects

According to a class action complaint filed against Palantir, between November 9, 2021 and May 6, 2022, defendants failed to disclose that Palantir's investments in marketable securities were having a significant negative impact on the Company's earnings per share ("EPS") results; (ii) Palantir overstated the sustainability of its government segment's growth and revenues; and (iii) Palantir was experiencing a significant slowdown in revenue growth, particularly among its government customers. As a result, Palantir was likely to and did miss consensus estimates for its first quarter 2022 ("Q1") EPS and second quarter 2022 ("Q2") sales outlook.

On May 9, 2022, Palantir issued a press release announcing its Q1 financial results and guidance for Q2. For Q1, Palantir announced adjusted EPS of $0.02, compared to analyst estimates of $0.04 per share, noting on a conference call that the "[f]irst quarter adjusted [EPS of] $0.02 . . . includes a negative $0.02 impact driven primarily by unrealized losses on marketable securities." The Company also disclosed that government revenue grew by only 16% year-over-year for Q1, representing a significant slowdown in revenue growth compared to prior quarters, and that, for Q2, the Company expected $470 million in sales, compared to estimates of $483.76 million. On this news, Palantir's stock price fell $2.02 per share, or over 21%, to close at $7.46 per share on May 9, 2022.

Next Steps: If you own shares of Palantir Technologies Inc. you have legal options. Please contact Robbins LLP for more information about your rights as a stockholder.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas (800) 350-6003 adumas@robbinsllp.com Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Palantir Technologies Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221125005378/en/

SOURCE: Robbins LLP">

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com 
(800) 350-6003
www.robbinsllp.com
comtex tracking

COMTEX_419690263/1006/2022-11-25T16:05:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.